Latest news with #MGITechCo.
Malaysian Reserve
22-05-2025
- Business
- Malaysian Reserve
MGI Tech Unveils Next-Generation Automation Portfolio at SLAS Europe 2025 in Germany
HAMBURG, Germany, May 21, 2025 /PRNewswire/ — MGI Tech Co., Ltd. (MGI), a company dedicated to developing core tools and technologies that drive innovation in life sciences, is proud to unveil its latest innovation, PrepALL, a flexible liquid handling system, along with the latest version of the Smart8 at SLAS Europe 2025, taking place from May 20–22 in Hamburg. Featuring advanced robotics, AI integration, and modular platforms, MGI's automation portfolio addresses critical challenges in genomics, drug discovery, synthetic biology, and molecular diagnostics—empowering labs of all sizes to scale research efficiently. PrepALL: Compact, Affordable Automation for Flexible Pipetting The PrepALL Flexible Liquid Handling Platform simplifies complex laboratory tasks while maintaining enterprise-level performance—without the high costs typically associated with traditional systems. Compact yet powerful, PrepALL is ideal for laboratories adopting automation for the first time or scaling existing research capacity. Key Features Include: Space-saving design: Occupies just 0.7 m², with 16 SBS deck positions (expandable to 41). High-precision pipetting: 8 independent channels support 0.5–1200 µL volumes with CVs (coefficients of variation) of less than 3% (1–50 µL) and <1% (50–1200 µL). It supports pLLD/cLLD, liquid level tracking, and anti-dripping, so that it reduces dead volume and improves pipetting accuracy. Plug-and-play setup and easy to use: Integrated with a visual system, it can achieve automatic consumables identification and automatic position calibration Full traceability: Built-in sensors and data logging ensure reproducibility and consistency. Leveraging advanced vision-based AI, PrepALL delivers high-precision performance in critical applications such as nucleic acid extraction, plasmid construction, sample preparation, and NGS library prep. Designed for global accessibility, it addresses cost and complexity barriers with a scalable, modular design and open APIs. Ideal for both entry-level and high-throughput environments, PrepALL empowers smaller labs to scale without costly infrastructure overhauls. 'PrepALL represents a major leap in lab automation, giving labs of all sizes the ability to streamline complex workflows with unmatched affordability and reliability. It's a bold step in our mission to democratize cutting-edge tools and accelerate scientific discovery worldwide.' said Dr. Christian Zimmerman, VP of Sales at MGI Europe and Africa. Scalable Automation Ecosystem for Every Lab MGI's automation portfolio is among the most versatile in the industry, designed to meet diverse laboratory needs while ensuring scalability and ease of use. At SLAS Europe 2025, MGI also presents Smart 8, a globally recognized solution launched in 2022. Smart 8 features eight-channel pipetting, and smart gripper technology. The new enhancement introduces AI-optimized pipetting for up to 20% faster cycle times, including nucleic acid extraction, microbial screening, and library preparation. This update ensures higher reproducibility and efficiency, making the Smart 8 an ideal partner for labs seeking reliable automation while remaining cost-effective. The enhanced capabilities of the Smart 8 will cater to academic institutions, biotech startups, and clinical labs, offering a competitive edge in high-throughput research. By reducing manual intervention, the system accelerates time-to-results, enabling researchers to focus on data analysis and discovery. Affordable, Scalable, Smart: The MGI Automation Edge MGI stands out in the lab automation market by prioritizing cost-effectiveness, scalability, and global accessibility. Designed to democratize advanced technology, MGI empowers researchers across diverse fields—from precision medicine to agriculture—regardless of budget constraints. MGI provides a comprehensive portfolio that covers the entire workflow, from sample extraction and preparation to sequencing and data analysis. This all-in-one solution enhance chances to meet customers' diversified demand under one system and brand and ensures compatibility among various systems, simplifying the overall experimental workflow. These advantages have positioned MGI as a trusted partner in more than 100 countries, accelerating breakthroughs in genomics, synthetic biology, and beyond. During global health crises, systems like the Platforms like the MGISP-960 and MGISTP-7000 have processed millions of samples, demonstrating MGI's ability to deliver robust solutions under pressure. MGI invites researchers, lab managers, and industry professionals to explore its latest automation solutions at SLAS Europe 2025. Visit MGI's booth#516 to see the enhanced innovations in action.
Yahoo
22-05-2025
- Business
- Yahoo
MGI Tech Unveils Next-Generation Automation Portfolio at SLAS Europe 2025 in Germany
HAMBURG, Germany, May 21, 2025 /PRNewswire/ -- MGI Tech Co., Ltd. (MGI), a company dedicated to developing core tools and technologies that drive innovation in life sciences, is proud to unveil its latest innovation, PrepALL, a flexible liquid handling system, along with the latest version of the Smart8 at SLAS Europe 2025, taking place from May 20–22 in Hamburg. Featuring advanced robotics, AI integration, and modular platforms, MGI's automation portfolio addresses critical challenges in genomics, drug discovery, synthetic biology, and molecular diagnostics—empowering labs of all sizes to scale research efficiently. PrepALL: Compact, Affordable Automation for Flexible Pipetting The PrepALL Flexible Liquid Handling Platform simplifies complex laboratory tasks while maintaining enterprise-level performance—without the high costs typically associated with traditional systems. Compact yet powerful, PrepALL is ideal for laboratories adopting automation for the first time or scaling existing research capacity. Key Features Include: Space-saving design: Occupies just 0.7 m², with 16 SBS deck positions (expandable to 41). High-precision pipetting: 8 independent channels support 0.5–1200 µL volumes with CVs (coefficients of variation) of less than 3% (1–50 µL) and <1% (50–1200 µL). It supports pLLD/cLLD, liquid level tracking, and anti-dripping, so that it reduces dead volume and improves pipetting accuracy. Plug-and-play setup and easy to use: Integrated with a visual system, it can achieve automatic consumables identification and automatic position calibration Full traceability: Built-in sensors and data logging ensure reproducibility and consistency. Leveraging advanced vision-based AI, PrepALL delivers high-precision performance in critical applications such as nucleic acid extraction, plasmid construction, sample preparation, and NGS library prep. Designed for global accessibility, it addresses cost and complexity barriers with a scalable, modular design and open APIs. Ideal for both entry-level and high-throughput environments, PrepALL empowers smaller labs to scale without costly infrastructure overhauls. "PrepALL represents a major leap in lab automation, giving labs of all sizes the ability to streamline complex workflows with unmatched affordability and reliability. It's a bold step in our mission to democratize cutting-edge tools and accelerate scientific discovery worldwide." said Dr. Christian Zimmerman, VP of Sales at MGI Europe and Africa. Scalable Automation Ecosystem for Every Lab MGI's automation portfolio is among the most versatile in the industry, designed to meet diverse laboratory needs while ensuring scalability and ease of use. At SLAS Europe 2025, MGI also presents Smart 8, a globally recognized solution launched in 2022. Smart 8 features eight-channel pipetting, and smart gripper technology. The new enhancement introduces AI-optimized pipetting for up to 20% faster cycle times, including nucleic acid extraction, microbial screening, and library preparation. This update ensures higher reproducibility and efficiency, making the Smart 8 an ideal partner for labs seeking reliable automation while remaining cost-effective. The enhanced capabilities of the Smart 8 will cater to academic institutions, biotech startups, and clinical labs, offering a competitive edge in high-throughput research. By reducing manual intervention, the system accelerates time-to-results, enabling researchers to focus on data analysis and discovery. Affordable, Scalable, Smart: The MGI Automation Edge MGI stands out in the lab automation market by prioritizing cost-effectiveness, scalability, and global accessibility. Designed to democratize advanced technology, MGI empowers researchers across diverse fields—from precision medicine to agriculture—regardless of budget constraints. MGI provides a comprehensive portfolio that covers the entire workflow, from sample extraction and preparation to sequencing and data analysis. This all-in-one solution enhance chances to meet customers' diversified demand under one system and brand and ensures compatibility among various systems, simplifying the overall experimental workflow. These advantages have positioned MGI as a trusted partner in more than 100 countries, accelerating breakthroughs in genomics, synthetic biology, and beyond. During global health crises, systems like the Platforms like the MGISP-960 and MGISTP-7000 have processed millions of samples, demonstrating MGI's ability to deliver robust solutions under pressure. MGI invites researchers, lab managers, and industry professionals to explore its latest automation solutions at SLAS Europe 2025. Visit MGI's booth#516 to see the enhanced innovations in action. View original content to download multimedia: SOURCE MGI TECH Sign in to access your portfolio
Yahoo
14-04-2025
- Business
- Yahoo
MGI Tech Celebrates 10 Years of DNBSEQ™ Technology: Driving Genomics Forward with Speed, Scale, and Accessibility
SHENZHEN, China, April 13, 2025 /PRNewswire/ -- MGI Tech Co., Ltd. ("MGI"), a company committed to building core tools and technologies that drive innovation in life science, proudly marks a decade since the commercialization of its proprietary DNBSEQ™ sequencing technology. Over the past ten years, DNBSEQ™ has transformed the landscape of genomics by delivering high-performance, cost-effective sequencing solutions that empower scientists, clinicians, and innovators across the globe. First commercial launched in 2015, DNBSEQ™ has become a trusted platform for cutting-edge research and diagnostics—spanning over 3,900 installations worldwide and contributing to more than 10,900 peer-reviewed publications*. Today, DNBSEQ™ continues to stand at the forefront of sequencing innovation, driving progress in precision medicine, public health, agriculture, biodiversity, and more. A Decade of Speed and Scale in Innovation Powered by proprietary DNA nanoball (DNB) technology and patterned arrays, DNBSEQ™ delivers exceptional accuracy, lower duplication rates, and minimal index hopping—resulting in high-quality data at significantly lower cost. These advantages make it an ideal choice for both large-scale studies and sensitive clinical technology has been widely praised by users for its outstanding data quality and cost-effectiveness in different applications, including whole-genome sequencing (WGS) and whole-exome sequencing (WES). Research has also identified the platform as an excellent candidate for eukaryotic genome sequencing, metagenomic sequencing, bacterial genome research, and more, demonstrating its versatility and reliability across scenarios. DNBSEQ™ has redefined the speed of innovation in genomic technology, offering the widest range of sequencing throughput and application coverage in the industry. Today, MGI offers a comprehensive portfolio of genetic sequencers based on DNBSEQä under T, G, and E series, including the ultra-high-throughput DNBSEQ-T20×2 which delivered the world's first sub-$100 human genome; the widely adopted DNBSEQ-T7 for high-throughput versatility; the ultra-compact DNBSEQ-E25 designed for fieldwork and decentralized testing; the benchtop DNBSEQ-G400;and the fastest in its class for mid-to-low throughput sequencing DNBSEQ-G99; MGI's newest flagship, the DNBSEQ-T1+, represents the latest evolution of this journey—an ultra-fast benchtop sequencer that balances power, speed, and flexibility. It reflects MGI's ongoing commitment to continuous innovation, empowering researchers to accelerate discovery without compromise. Enabling Multi-Omics and Real-World Impact More than a sequencing platform, DNBSEQ™ enables a wide range of multi-omics applications—including genomics, transcriptomics, epigenomics, single-cell, and spatial omics. These capabilities make it a powerful tool across diverse scientific fields, enabling deeper insights into disease mechanisms, environmental interactions, and biological systems. Proven in extreme environments—from the depths of the Mariana Trench to the peak of Mount Everest—DNBSEQ™ continues to deliver high-quality, reliable results wherever science needs to go. End-to-End Solutions: Making Science Simpler MGI complements its sequencing platforms with a suite of automation and BIT tools that deliver a seamless end-to-end workflow—from sample preparation to data analysis. These integrated solutions improve efficiency, reduce manual effort, and bring advanced genomic tools within reach for more users, regardless of lab size or location. Inspired by the question "What if science had no barriers?", MGI's technology ecosystem is designed to remove bottlenecks and lower costs, enabling researchers to focus on discovery—not complexity. Toward the $10 Genome and a More Equitable Future As MGI looks to the future, the company is focused on achieving its most ambitious goal yet: the $10 genome. Building on the foundation of DNBSEQ™, MGI is developing next-generation sequencing technologies to further reduce costs, increase accessibility, and accelerate time to insight. "Over the past decade, DNBSEQ™ has grown from an innovation into a global standard for high-quality, affordable sequencing," said Dr. Rade Drmanac, Chief Scientific Officer at MGI. "We've opened doors for researchers everywhere—and now, we're building the next chapter in accessible genomics." Genomics for All: The Mission Continues Celebrating 10 years of DNBSEQ™ is more than a technological milestone—it is a reaffirmation of MGI's mission: to make genomics accessible, affordable, and impactful for all. By delivering the tools that drive discovery, MGI is helping to build a healthier, more informed, and more connected world—one genome at a time. For more information on DNBSEQ™ technology and MGI's full product portfolio, visit: * statistics as of 30 Jun 2024 About MGI MGI Tech Co., Ltd. (or its subsidiaries, together referred to MGI), is committed to building core tools and technologies that drive innovation in life science. Our focus lies in research & development, manufacturing, and sales of instruments, reagents, and related products in the field of life science and biotechnology. We provide real-time, multi-omics, and full spectrum of digital equipment and systems for precision medicine, agriculture, healthcare and various other industries. Founded in 2016, MGI has grown into a leader in life science, serving customers across six continents and have established research, manufacturing, training, and after-sales service facilities globally. MGI stands out as one of the few companies capable of independently developing and mass-producing clinical-grade gene sequencers with varying throughput capacities, ranging from Gb to Tb levels. With unparalleled expertise, cutting-edge products, and a commitment to global impact, MGI continues to shape the trajectory of life sciences into the future. To learn more, please visit , Linkedin, X, and Youtube. View original content to download multimedia: SOURCE MGI TECH Sign in to access your portfolio
